UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): June 21,
2018
AMERICAN BIO MEDICA
CORPORATION
(Exact
name of registrant as specified in its charter)
|
New
York
|
|
0-28666
|
|
14-1702188
|
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification Number)
|
|
122 Smith Road,
Kinderhook, NY
|
|
12106
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 518-758-8158
Not applicable
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see
General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging
growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM 5.07
Submission of Matters to a Vote of Security Holders
At the
Annual Meeting of the Shareholders of the Company held on June 21,
2018 (the “Annual Meeting”), at the Company’s
corporate offices in Kinderhook, New York, the following matters
were voted upon.
PROPOSAL
NUMBER 1 – ELECTION OF DIRECTORS
|
Total Shares in Attendance:
|
28,493,494
|
Total Shares Outstanding (as of April 20,
2018):
29,932,770
|
|||
|
Percent of Shares Voted:
|
95.2%
|
||||
|
Director
|
For
|
Percent
|
Withheld
|
Percent
|
Broker Non-Votes
|
|
Melissa A. Waterhouse
|
11,748,494
|
77.1
|
3,496,587
|
22.9
|
13,248,313
|
|
Peter Jerome
|
15,067,114
|
98.8
|
177,967
|
1.2
|
13,248,313
|
PROPOSAL
NUMBER 2 – RATIFICATION OF AUDITORS
|
Total Shares in Attendance:
|
28,493,494
|
Total Shares Outstanding (as of April 20,
2018):
29,932,770
|
||||
|
Percent of Shares Voted:
|
95.2%
|
|||||
|
For
|
Percent
|
Against
|
Percent
|
Abstain
|
Percent
|
Broker Non-Votes
|
|
28,313,066
|
99.4
|
112,391
|
0.4
|
63,037
|
0.2
|
0
|
A
description of the proposals can be found in the Company’s
definitive proxy statement for the Annual Meeting filed with the
U.S. Securities and Exchange Commission on April 20,
2018.
The
nominees for election to the Board of Directors were each elected
for a three-year term ending in 2021, or until their successor(s)
is/are elected and duly qualified. In addition to the directors
elected at the Annual Meeting, Chaim Davis, Jean Neff and Diane
Generous continued their terms of office after the Annual
Meeting.
There
were no other matters voted upon at the Annual Meeting other than
the Proposals noted above.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AMERICAN BIO MEDICA
CORPORATION
(Registrant)
|
|
|
|
|
|
|
|
|
Dated: June 26,
2018
|
By:
|
/s/
Melissa
A. Waterhouse
|
|
|
|
|
Melissa A.
Waterhouse
|
|
|
|
|
Chief Executive
Officer (Principal Executive Officer)
Principal Financial
Officer
|
|